Searched for
GLENMARK SHARE PRICE
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Two Trades for Today: A pharma major for a 6% upmove, a mid-cap healthcare stock for a gain of about 5%Our technical analysts identify select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Stock Radar: Glenmark Pharma breaks out from a range to hit fresh record high in March 2026; what should investors do?Glenmark Pharma Ltd has broken out of a 7-month consolidation on weekly charts, reaching fresh record highs. Experts suggest short-term tra...
- Two Trades for Today: Two pharma stocks, one a mid-cap for a 6.7% gain, the other a large-cap for an upmove of almost 6%Our technical analysts identify select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.
- Glenmark shares in focus after recall of 15 lakh bottles of ADHD drug in USGlenmark share price: The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark Pharm...
- Glenmark Pharma to sell 7.84% stake in Glenmark Life via OFSThe stake sale will be done through the stock exchanges via an offer for sale (OFS). The decision was made at a meeting held today, and the...
- Glenmark Pharma shares fall over 6% on subsidiary stake sale to NirmaGlenmark Pharmaceuticals has entered into a definitive agreement with Nirma to divest a 75% stake in Glenmark Life Sciences for Rs 5,651.5 ...
- Buy Glenmark Pharma, target price Rs 560: Yes SecuritiesGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a mid-cap company (with a market cap of Rs 14826.53 crore) operating in ph...
- Interim data from study supports Favipiravir's safety, effectiveness: GlenmarkThe study, commenced in July 2020, aimed to evaluate safety and efficacy of favipiravir in mild to moderate COVID-19 patients.
- Glenmark drops 6% as Q2 net profit declinesThe stock has nearly trebled from its March lows of Rs 168, and is up 39 per cent year-to-date.
- Glenmark Pharma surges 7% as Q1 net profit doubles to Rs 254 croreConsolidated revenue stood at Rs 2,344.78 crore for the first quarter compared with Rs 2,322.87 crore in the year-ago period, Glenmark Phar...
- Buy Glenmark Pharmaceuticals, target Rs 660: Kunal BothraBuy Glenmark Pharmaceuticals Ltd. at a price target of Rs 660.0 and a stoploss at Rs 620 from entry point.
- Buy Glenmark Pharmaceuticals, target Rs 610: Manas JaiswalBuy Glenmark Pharmaceuticals Ltd. at a price target of Rs 610.0 and a stop loss at Rs 567 from the entry point.
Load More
